A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Phase 2TerminatedNCT02109016

Clovis Oncology, Inc.18 enrolled

Overview

The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGF), or platelet derived growth factor (PDGF) related genetic alterations.

Lucitanib is an oral inhibitor of the tyrosine kinase activity of FGFR 1-3, VEGFR 1-3, and PDGFR α/β. Lucitanib has demonstrated potent anti-tumor and anti-angiogenic activity in vitro proliferation assays and in vivo using human tumor xenograft models, with a trend for stronger efficacy in those with genomic aberrancies of FGF or PDGF. Abnormalities in the FGF, VEGF, and PDGF-related genes are observed across lung cancer histologies. The first in human trial of lucitanib demonstrated that daily lucitanib is clinically active in patients with advanced solid tumors. Specifically, patients with FGFR1-amplification appeared to derive particular benefit from lucitanib. Based on these results, this study is designed to explore the safety and anti-tumor activity of daily lucitanib in lung cancer patients with FGF, VEGF, and PDGF genetic alterations.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Small Cell Lung Cancer Squamous Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC * Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2, or FGFR3 activating mutation * Availability of tumor tissue sample suitable for the central confirmation of the genetic alteration and exploratory analyses * Eastern Cooperative Oncology Group (ECOG) of 0 or 1 * Measurable disease per RECIST 1.1 * Documented radiographic disease progression following at least one line of therapy in the advanced/metastatic setting Exclusion Criteria: * Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel * Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with optimized anti-hypertensive therapy * Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy * Symptomatic and/or untreated central nervous system metastases * Presence of another active cancer * Ongoing adverse events from surgery or prior anti-cancer therapies, including radiation, targeted, or cytotoxic therapies * Pregnant or breastfeeding women

Locations (19)

University of California, Los Angeles

Los Angeles, California, United States

University of Colorado

Aurora, Colorado, United States

Georgetown University

Washington D.C., District of Columbia, United States

Emory University

Atlanta, Georgia, United States

Associates in Oncology and Hematology

Rockville, Maryland, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Tennessee Oncology

Nashville, Tennessee, United States

CHU Caen, Hôpital de la Côte de Nacre

Caen, France

CHRU Lille, Hôpital Albert Calmette

Lille, France

Hôpital Nord

Marseille, France

...and 9 more locations

Outcomes

Primary Outcomes

Objective Response Rate (ORR)

Proportion of patients in whom a confirmed Complete Response (CR) or a confirmed Partial Response (PR), as best overall response according to RECIST criteria, is observed.